Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?

被引：1

作者：

Addeo, Alfredo ^{[1
]}

Bahl, Amit ^{[1
]}

机构：

[1] Bristol Canc Inst, Bristol, Avon, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期

关键词：

SURVIVAL;

D O I：

10.1200/JCO.2015.62.8537

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：387 / +

页数：2

相关论文

共 2 条

[1] Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study [J].

Fizazi, Karim ;

Scher, Howard I. ;

Molina, Arturo ;

Logothetis, Christopher J. ;

Chi, Kim N. ;

Jones, Robert J. ;

Staffurth, John N. ;

North, Scott ;

Vogelzang, Nicholas J. ;

Saad, Fred ;

Mainwaring, Paul ;

Harland, Stephen ;

Goodman, Oscar B., Jr. ;

Sternberg, Cora N. ;

Li, Jin Hui ;

Kheoh, Thian ;

Haqq, Christopher M. ;

de Bono, Johann S. .

LANCET ONCOLOGY, 2012, 13 (10) :983-992

[2] Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer [J].

Scher, Howard I. ;

Heller, Glenn ;

Molina, Arturo ;

Attard, Gerhardt ;

Danila, Daniel C. ;

Jia, Xiaoyu ;

Peng, Weimin ;

Sandhu, Shahneen K. ;

Olmos, David ;

Riisnaes, Ruth ;

McCormack, Robert ;

Burzykowski, Tomasz ;

Kheoh, Thian ;

Fleisher, Martin ;

Buyse, Marc ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (12) :1348-+